Edwards Lifesciences EW Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Europe | $442.6M+8.1% | $409.6M+5.6% | $387.9M+2.6% | $378.2M+10.6% | $341.8M-0.6% | |
| Japan | $90.6M+3.5% | $87.5M-2.9% | $90.1M-5.5% | $95.3M+16.5% | $81.8M-4.8% | |
| Rest of World | $177.8M+7.4% | $165.5M-1.3% | $167.6M-0.8% | $169M+12.5% | $150.2M+4.8% | |
| United States | $937.6M+3.4% | $907M-0.1% | $907.5M+2.0% | $889.7M+6.1% | $838.9M+3.2% | |
| Total other segment items by Business | ||||||
| Europe | $41.9M+37.8% | $30.4M+5.2% | $28.9M+90.1% | $15.2M+283% | -$8.3M-260% | |
| Japan | -$6M-39.5% | -$4.3M-378% | -$900K-350% | -$200K+95.7% | -$4.6M-207% | |
| Rest of World | -$7.5M-63.0% | -$4.6M+2.1% | -$4.7M+40.5% | -$7.9M+14.1% | -$9.2M-149% | |
| United States | $800K+33.3% | $600K-14.3% | $700K+16.7% | $600K0.0% | $600K+50.0% | |
| Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest by Business | ||||||
| Europe | $235.3M+23.1% | $191.1M-7.5% | $206.6M+1.3% | $204M+4.9% | $194.5M+5.2% | |
| Japan | $66.4M+25.5% | $52.9M-11.5% | $59.8M-5.7% | $63.4M+9.9% | $57.7M+7.6% | |
| Rest of World | $89.7M+65.2% | $54.3M-33.8% | $82M-3.2% | $84.7M+9.3% | $77.5M+32.9% | |
| United States | $610.7M+1.7% | $600.5M+0.2% | $599.5M+2.3% | $585.9M+4.8% | $559.1M+3.6% | |
| Selling, general, and administrative expenses by Business | ||||||
| Europe | $71.8M-26.3% | $97.4M+39.1% | $70M-5.7% | $74.2M+1.1% | $73.4M-2.5% | |
| Japan | $15.9M-38.1% | $25.7M+43.6% | $17.9M-3.2% | $18.5M+12.8% | $16.4M-24.8% | |
| Rest of World | $48M-31.1% | $69.7M+40.8% | $49.5M+2.5% | $48.3M+14.7% | $42.1M-16.3% | |
| United States | $154.1M-7.3% | $166.2M+18.5% | $140.2M+3.3% | $135.7M+1.9% | $133.2M-4.0% | |
| Cost of Sales by Business | ||||||
| Europe | $93.6M+3.2% | $90.7M+10.1% | $82.4M-2.8% | $84.8M+3.2% | $82.2M+4.8% | |
| Japan | $14.3M+8.3% | $13.2M-0.8% | $13.3M-2.2% | $13.6M+10.6% | $12.3M+2.5% | |
| Rest of World | $47.6M+3.3% | $46.1M+13.0% | $40.8M-7.1% | $43.9M+10.3% | $39.8M+3.6% | |
| United States | $172M+23.1% | $139.7M-16.4% | $167.1M-0.2% | $167.5M+14.7% | $146M+9.0% | |
| Net Sales by Product | ||||||
| Surgical | $276.2M— | —— | —— | —— | $250.9M— | |
| Transcatheter Aortic Valve Replacement | $1.2B+3.2% | $1.16B+0.9% | $1.15B+1.7% | $1.13B+8.1% | $1.05B+1.0% | |
| Transcatheter Mitral and Tricuspid Therapies | $175.1M+12.5% | $155.7M+7.2% | $145.2M+8.0% | $134.5M+16.8% | $115.2M+9.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Edwards Lifesciences break its business down?
- Edwards Lifesciences (EW) reports net sales by business across 4 parts — Europe, Japan, Rest of World and United States. Each is extracted from the segment footnotes and tracked over time.
- Where does Edwards Lifesciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Edwards Lifesciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
